^
    Back
    Association details:
    Biomarker:BRAF D594G
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) +
    ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).

    Published date:
    05/26/2022
    Excerpt:
    ULI-EAP-100 (NCT04566393) is an ongoing intermediate expanded access protocol (EAP) that offers ulixertinib to US patients with advanced solid tumors harboring MAPK pathway alterations..a BRAF V600E CRC pt experienced a complete response following ulixertinib + encorafenib + cetuximab combination therapy.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e15101
    Trial ID:
    NCT04566393